Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn’s Disease: A Nationwide, Multicenter Study
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.
Abstract
Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.
참고문헌 (40)
- Lichtenstein GR, "Management of Crohn’s disease in adults", Am J Gastroenterol, 104, pp.465~483 (2009)
- Van Assche G, "The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis", J Crohns Colitis, 4, pp.7~27 (2010)
- Tozer PJ, "Etiology of perianal Crohn’s disease: role of genetic, microbiological, and immunological factors", Inflamm Bowel Dis, 15, pp.1591~1598 (2009)
- Ford AC, "Effcacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis", Am J Gastroenterol, 106, pp.617~629 (2011)
- Khan KJ, "Effcacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis", Am J Gastroenterol, 106, pp.630~642 (2011)
- Turner D, "Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression", Clin Gastroenterol Hepatol, 5, pp.103~110 (2007)
- Knight DM, "Construction and initial characterization of a mouse-human chimeric anti-TNF antibody", Mol Immunol, 30, pp.1443~1453 (1993)
- Plevy SE, "A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease", J Immunol, 159, pp.6276~6282 (1997)
- D’Haens GR, "The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?", Am J Gastroenterol, 106, pp.199~212 (2011)
- Dignass A, "The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management", J Crohns Colitis, 4, pp.28~62 (2010)
- Hamzaoglu H, "Safety of infliximab in Crohn’s disease: a large singlecenter experience", Inflamm Bowel Dis, 16, pp.2109~2116 (2010)
- Park SK, "Risk and clinical characteristics of lymphoma in Korean patients with inflam-matory bowel diseases: a multicenter study", J Clin Gastroenterol, 49, pp.e11~e16 (2015)
- Ng SC, "Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis", Inflamm Bowel Dis, 18, pp.1164~1176 (2012)
- Ha C, "Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population", Clin Gastroenterol Hepatol, 10, pp.1002~1007 (2012)
- 조경욱, "Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study", Tuberculosis and Respiratory Diseases, 75(1), pp.18~24 (2013), 대한결핵및호흡기학회
- Lee CH, "Active pulmonary tuberculosis and latent tuberculosis infection among homeless people in Seoul, South Korea: a cross-sectional study", BMC Public Health, 13, pp.720~ (2013)
- Lennard-Jones JE, "Classification of inflammatory bowel disease", Scand J Gastroenterol Suppl, 170, pp.2~6 (1989)
- Hanauer SB, "Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
- Sands BE, "Infliximab maintenance therapy for fistulizing Crohn’s disease", N Engl J Med, 350, pp.876~885 (2004)
- Maini RN, "Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate", Arthritis Rheum, 50, pp.1051~1065 (2004)
- Ardizzone S, "Infliximab in treatment of Crohn’s disease: the Milan experience", Dig Liver Dis, 34, pp.411~418 (2002)
- 김연주, "단일 기관에서 경험한 크론병에서 Infliximab의 치료 효과", 대한소화기학회지, 61(5), pp.270~278 (2013), 대한소화기학회
- Orlando A, "Infliximab in the treatment of Crohn’s disease: predictors of response in an Italian multicentric open study", Dig Liver Dis, 37, pp.577~583 (2005)
- Present DH, "Infliximab for the treatment of fistulas in patients with Crohn’s disease", N Engl J Med, 340, pp.1398~1405 (1999)
- Targan SR, "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group", N Engl J Med, 337, pp.1029~1035 (1997)
- Bouguen G, "Treat to target: a proposed new paradigm for the management of Crohn’s disease", Clin Gastroenterol Hepatol, 13, pp.1042.e2~1050.e2 (2015)
- D’Haens GR, "Future directions in inflammatory bowel disease management", J Crohns Colitis, 8, pp.726~734 (2014)
- Peyrin-Biroulet L, "Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease", J Crohns Colitis, 5, pp.477~483 (2011)
- Rutgeerts P, "Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial", Gastroenterology, 142, pp.1102.e2~1111.e2 (2012)
- Colombel JF, "Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)
- D’Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease:an open randomised trial", Lancet, 371, pp.660~667 (2008)
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn’s disease", N Engl J Med, 362, pp.1383~1395 (2010)
- Centers for Disease Control and Prevention (CDC), "Trends in tuberculosis--United States, 2012", MMWR Morb Mortal Wkly Rep, 62, pp.201~205 (2013)
- 심태선, "Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy", Intestinal research, 12(1), pp.12~19 (2014), 대한장연구학회
- Dixon WG, "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)", Ann Rheum Dis, 69, pp.522~528 (2010)
- Lee SK, "Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea", Lung, 191, pp.565~571 (2013)
- Marehbian J, "Adverse events associated with common therapy regimens for moderateto-severe Crohn’s disease", Am J Gastroenterol, 104, pp.2524~2533 (2009)
- Tubach F, "Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry", Arthritis Rheum, 60, pp.1884~1894 (2009)
- 유인경, "Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy", Yonsei Medical Journal, 55(2), pp.442~448 (2014), 연세대학교의과대학[DOI]
- Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "Korean guidelines for tuberculosis. 2nd ed", Korea Centers for Disease Control and Prevention, ~ (2014)